Testimonials

Background stories of how others approached and experienced their European Horizon funding trajectory.

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Published on | 1 year ago

Programmes Health

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.

Read the full article for details 
Other available testimonials

Testimonial

image of SeaFoodTomorrow - improving the safety and dietary properties of seafood

SeaFoodTomorrow - improving the safety and dietary properties of seafood

The Project SeafoodTomorrow is a project that is approved within the call BG-08-2017: Innovative sustainable solutions for improving the safety and dietary properties of seafood.

The three-year SeafoodTomorrow project brings together 34 partners. From Flanders, ILVO takes part in the project.They are responsible for setting up two databases which are the central point of the project to gather all the project data from analysis and assessement. ILVO is also leader of the workpackage dealing with authenticity, traceability and labelling. ILVO is also involved a the workpackage about novel food preparation. And in the managerial part, ILVO is head of the IPC- Intellectual Property Comité.